HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) All Versions of this Article: adc.2006.107581v1 92/10/842    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in ADC Online Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cipolli, M. Articles by Gaskin, K. Search for Related Content PubMed PubMed Citation Articles by Cipolli, M. Articles by Gaskin, K. Topic Collections Related Articles

Pancreatic phenotype in infants with cystic fibrosis identified by mutation screening

¹ Cystic Fibrosis Centre, Azienda Ospedaliera di Verona, Verona, Italy
² New South Wales Newborn Screening Program, The Children’s Hospital at Westmead, Westmead, NSW, Australia
³ Department of Respiratory Medicine, The Children’s Hospital at Westmead, Westmead, NSW, Australia
⁵ James Fairfax Institute of Paediatric Nutrition, Discipline of Paediatrics and Child Health, University of Sydney, Sydney, Australia

Correspondence to:
Dr Marco Cipolli, Cystic Fibrosis Centre, Azienda Ospedaliera di Verona, Piazzale Stefani 1, 37126 Verona, Italy; marco.cipolli{at}azosp.vr.it

Objective: To determine the pancreatic phenotype of infants with cystic fibrosis (CF) diagnosed in the first week of life by a combined immunoreactive trypsin/mutation screening program.

Design: A prospective evaluation of pancreatic function in infants with CF at the time of neonatal diagnosis and up to the age of 12.

Setting: Two different centres (Verona, Italy and Westmead, Australia) to enable comparison of results between two regions where <60% or 90% of patients, respectively, have at least one single F508 a mutation.

Patients: 315 children with CF including 149 at Verona and 166 at Westmead.

Interventions: Fat balance studies over 3–5 days and pancreatic stimulation tests with main outcome measures being faecal fat or pancreatic colipase secretion. Patients with malabsorption are pancreatic insufficient (PI) or with normal absorption and pancreatic sufficient (PS).

Results: 34 infants (23%) at Verona and 46 (28%) at Westmead were PS at diagnosis. 15% of those with two class I, II or III "severe" mutations and 26/28 (93%) of those with class IV or V mutations were PS at this early age. Of the 80 infants with PS, 20 became PI before the age of 12. All 20 had two severe mutations.

Conclusion: Neonatal mutational screening programs for CF are less likely to detect PS patients with non-F508 mutations. Of PS patients who are detected, those with two severe class I, II or III mutations are at particularly high risk of becoming PI during early childhood.

This article has been cited by other articles:

				I. Doull What and when to collect from infants with cystic fibrosis Arch. Dis. Child., October 1, 2007; 92(10): 831 - 832. [Full Text] [PDF]